Publication | Closed Access

A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo

Cell-based Drug DeliveryNanomedicineMedicinal ChemistryDrug TargetingNanotherapeuticsEngineeringPolymer-drug ConjugateMedicineDrug Delivery SystemsNano-drug DeliveryImmunotherapeuticsAnticancer AgentsBiomedical EngineeringTumor TargetingPharmacologyTargeted Co-delivery